Invention Grant
- Patent Title: MR1 restricted T cell receptors for cancer immunotherapy
-
Application No.: US16563987Application Date: 2019-09-09
-
Publication No.: US11702459B2Publication Date: 2023-07-18
- Inventor: Gennaro De Libero , Marco Lepore , Lucia Mori
- Applicant: UNIVERSITÄT BASEL
- Applicant Address: CH Basel
- Assignee: UNIVERSITÄT BASEL
- Current Assignee: UNIVERSITÄT BASEL
- Current Assignee Address: CH Basel
- Agency: JMB Davis Ben-David
- Priority: EP 159754 2017.03.07 EP 179309 2017.07.03 EP 194025 2018.09.12
- Main IPC: C07K14/725
- IPC: C07K14/725 ; C12N5/0783 ; G01N1/30 ; G01N33/569 ; C12N5/09 ; C12N15/85 ; A61K35/17 ; A61P35/00

Abstract:
The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells.
The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.
The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.
Public/Granted literature
- US20190389926A1 MR1 RESTRICTED T CELL RECEPTORS FOR CANCER IMMUNOTHERAPY Public/Granted day:2019-12-26
Information query